Nav: Home

Two for the price of one: Mechanistic insights lead to drug repositioning

March 07, 2019

Tsukuba, Japan - Lung adenocarcinoma is the most common type of lung cancer. Although various targeted drugs have been developed to treat it, they do not markedly improve the survival of patients. Part of the explanation for this impasse is a poor understanding of the molecular causes of this disease during the early stages.

A new study reported in the journal Clinical Cancer Research has raised hopes in this field by revealing how a cancer-promoting protein called stratifin causes lung adenocarcinoma to emerge. This finding by researchers at University of Tsukuba also enabled the identification of two drugs, currently used for treating other health conditions, which are promising for treating this type of lung cancer.

Building on previous work, the team analyzed how and when stratifin binds to SKP1. SKP1 is one component of a larger cellular complex that normally labels molecules in a process called ubiquitination, which condemns these labeled molecules to degradation. The researchers showed that a reversible modification of SKP1 promotes its binding to stratifin, rather than its typical inclusion within the ubiquitination-related complex.

"We used the overexpression of stratifin as well as its blocking by siRNA to clarify the effects on SKP1 in a lung adenocarcinoma cell line," Masayuki Noguchi says. "The blocking of stratifin meant that SKP1 remained stable and could function in promoting the ubiquitination of errant proteins, some of which could be cancerous if not degraded by this process."

Based on these findings, the team then undertook computer-based drug screening to find plausible candidates that could inhibit stratifin and prevent its binding to SKP1 and consequent disruption of ubiquitination. This screening of a database of drugs already in clinical use identified four promising candidates that were then narrowed down to two after testing their efficacy on lung cancer cells.

"We then performed additional testing of these two drugs on mice that had been injected with lung cancer cells," lead author Aya Shiba-Ishii says. "We administered each of these drugs either the day after this injection or once tumor establishment had been confirmed. Our findings showed their success at blocking tumor formation or stopping or reversing the progression of tumors once they had formed."

This novel approach of focusing on epigenetic changes early in adenocarcinogenesis raises hopes about more powerful tools to treat this condition. This work also shows the value of drug repositioning for lung cancer, given that such drugs have already passed through clinical trials and had their safety in humans confirmed.
-end-


University of Tsukuba

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...